EMBC Q2 2026 Earnings Call Summary

Summary of Embecta Corp. Q2 2026 Earnings Call

1. Key Financial Results and Metrics

Revenue: $222 million, down 14.4% year-over-year (17.4% adjusted for constant currency).
- U.S. Revenue: Approximately $95 million, a decline of 29.4% (adjusted constant currency).
- International Revenue: Approximately $126 million, up 2.1% (down 4.1% adjusted for constant currency).
Gross Profit: GAAP gross profit of $127.8 million (57.6% margin), down from $164.1 million (63.4% margin) year-over-year.
Operating Income: GAAP operating income of $35 million (15.8% margin), compared to $62.9 million (24.3% margin) in the prior year.
Net Loss: GAAP net loss of $4.1 million, compared to net income of $23.5 million in the prior year.
Adjusted EPS: $0.27, down from $0.70 year-over-year.
Free Cash Flow: Approximately $47 million generated in the first half of the year.

2. Strategic Updates and Business Highlights

Acquisition of Owen Mumford: Expected to close by the end of the month, contributing approximately $30 million in revenue for the fiscal year.
Brand Transition: Over 75% of revenue now comes from products launched under the embecta label, with a goal for substantial completion by the end of 2026.
Product Development: Progress in developing market-appropriate pen needles and syringes, with new products launched in China and regulatory submissions underway in the U.S. and Europe.
B2B Strategy: Expansion in partnerships for GLP-1 therapies, with approximately 40% of identified partners in active negotiations or agreements.

3. Forward Guidance and Outlook

Revised Revenue Guidance: Updated to a range of $1.015 billion to $1.035 billion, down from $1.071 billion to $1.093 billion.
Adjusted Operating Margin Guidance: Lowered to 22.25% - 23.25% from 29% - 30%.
Adjusted EPS Guidance: Revised to $1.55 - $1.75, down from $2.80 - $3.00.
Debt Repayment Target: Continued focus on repaying approximately $150 million in debt during 2026.

4. Bad News, Challenges, or Points of Concern

U.S. Revenue Decline: Significant share loss in the pen needle category, particularly concentrated at a single customer, alongside overall market volume softness.
Market Dynamics: Decline in insulin pen prescriptions, attributed to competitive pressures and shifts in purchasing patterns towards lower-cost channels.
Product Line Issues: Discontinuation of alcohol swabs due to supplier issues, contributing to revenue loss.
Increased Tax Rate: Adjusted tax rate expected to rise to approximately 28%, impacting net income.

5. Notable Q&A Insights

Competitive Loss: The share loss is deeper than anticipated, with implications for revenue due to patients switching to competitors not on preferred plans.
Market Trends: Decline in insulin prescriptions is linked to the affordability of GLP-1 drugs and the expiration of ACA subsidies.
Future Growth: Management remains optimistic about returning to revenue growth, particularly through the Owen Mumford acquisition and expanding product offerings.
Contract Renewal Strategy: Efforts are underway to regain lost share, with management indicating they do not expect this to be a multiyear effort.

Overall, while Embecta faced significant challenges in Q2 2026, particularly in the U.S. market, the company is actively pursuing strategic initiatives to diversify its product offerings and stabilize its revenue base moving forward.

EMBC — Embecta Corp.